First-of-Its-Kind “Pathways to Dairy Net Zero” Initiative to Raise Climate Ambition for the Global Dairy Sector
A first-of-its-kind Pathways to Dairy Net Zero initiative is being developed to accelerate climate change action throughout the global dairy sector. Announced today at the United Nations (UN) Food Systems Pre-Summit, the climate effort will be unlike any other in agriculture in terms of size, breadth, and scope.
“The global dairy sector is creating this ground-breaking initiative to help speed climate action already underway, while continuing to provide livelihoods for a billion people and important nutrition for six billion people,” said Donald Moore, Executive Director at the Global Dairy Platform.
A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop methodologies, tools and pathways that work for every dairy system. Pathways to Dairy Net Zero will officially launch during the UN Food Systems Summit in September and aims to generate commitments at the UN Climate Change Conference, COP26, in November.
New research to guide the initiative
Research is underway to identify where positive climate change action is possible across all dairy production systems and regions throughout the world. The study is being conducted by the Global Research Alliance on Agricultural Greenhouse Gases (GRA), the UN Food and Agriculture Organisation, Scotland’s Rural College and the New Zealand Agricultural Greenhouse Gas Research Centre. Preliminary findings include:
- Positive change is possible across all dairy systems and regions. Although there is a wide variety of production systems globally, there are opportunities for all to reduce greenhouse gas emission (GHG) intensity.1
- Collaboration is needed to reduce dairy’s emissions. Many climate, poverty, and malnutrition challenges can be addressed through adoption of best practices in similar dairy systems.2
- Reducing methane may be key to fast results. Methane, a primary GHG produced by ruminant livestock, is short-lived. As a result, more reductions in methane would have a more immediate effect on warming.3
- Dairy already has the means to reduce a significant proportion of emissions. 4 Initial evidence suggests emissions can be reduced up to 40 percent in some systems by improving productivity and resource use efficiency.
- Defining terminologies and targets will focus efforts to achieve the best results. As indicated in the Intergovernmental Panel on Climate Change (IPCC) Special Report: Global Warming of 1.5°C, dairy’s carbon dioxide emissions need to strive to Net Zero, but its methane reduction can range from 24-47 percent, and its nitrous oxide reduction can be 26 percent.5
“Our initial analysis suggests that wider use of existing GHG mitigation technologies will make an important impact in reducing dairy’s emissions in the short term, while the development of new innovations takes place,” said Hayden Montgomery, Special Representative of GRA. “This initiative may ultimately act as a blueprint for other livestock sectors,” he added.
For more information about Pathways to Dairy Net Zero, visit: www.GlobalDairyPlatform.com/PathwaysToDairyNetZero.
You can register here for the UN Food Systems Pre-Summit affiliated session “Raising the climate ambition for the agriculture sector: An approach from dairy” on Monday, July 26, at 19:30 CEST.
References:
- Food and Agriculture Organization of the United Nations (FAO). 2010. Greenhouse Gas Emissions from the Dairy Sector: A Life Cycle Assessment. Available at: http://www.fao.org/3/k7930e/k7930e00.pdf [Accessed July 2021].
- Food and Agriculture Organization of the United Nations (FAO). 2019. Climate change and the global dairy cattle sector: The role of the dairy sector in a low‐carbon future. Available at: http://www.fao.org/3/CA2929EN/ca2929en.pdf [Accessed July 2021].
- UN Environment Programme. 2021. Global Methane Assessment: Benefits and Costs of Mitigating Methane Emissions. Available at: https://www.unep.org/resources/report/global-methane-assessment-benefits-and-costs-mitigating-methane-emissions [Accessed July 2021].
- Gerber PJ, Steinfeld H, Henderson B, et al. 2013. Tackling climate change through livestock – A global assessment of emissions and mitigation opportunities. Food and Agriculture Organization of the United Nations (FAO), Rome. Available at: http://www.fao.org/3/i3437e/i3437e.pdf [Accessed July 2021].
- The Intergovernmental Panel on Climate Change (IPCC). 2018. Global warming of 1.5°C. An IPCC Special Report on the impacts of global warming of 1.5°C above pre-industrial levels and related global greenhouse gas emission pathways, in the context of strengthening the global response to the threat of climate change, sustainable development, and efforts to eradicate poverty. Available at: https://www.ipcc.ch/site/assets/uploads/sites/2/2019/06/SR15_Full_Report_Low_Res.pdf [Accessed July 2021].
About Pathways to Dairy Net Zero
This is a vibrant, growing movement, the first of its kind in the world. It brings together dairy production systems of every size and type, as well as organizations throughout the dairy supply chain. Collaborators include Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network. The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.
www.GlobalDairyPlatform.com/PathwaysToDairyNetZero
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005299/en/
Contact information
Kevin Burkum, Director of Communications
+1 847-627-3387
Kevin.Burkum@GlobalDairyPlatform.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
